Cellarium™ devices are based on bioresorbable polymer scaffolds containing bioactive factors that are preprogrammed to function or be released in a temporally controlled fashion. This proprietary technology enables the unprecedented control of in vivo cell selection, gathering, proliferation, maturation and enhanced, functional, cellular integration within the body’s native processes and tissues.

 The characterized and validated immunotherapeutic product has demonstrated reproducible efficacy in a wide array of clinically relevant preclinical models. Portions of the development work is published in peer reviewed journals.

The Cellarium Immunotherapeutic product (Cancer Vaccine) is comprised of four active components:

• A PLG resorbable porous scaffold 
• A cytokine to specifically attract dendritic cells
• An adjuvant and
• Markers for the tumor to be targeted

When placed subcutaneously the 8.5 mm x 2 mm thick disk attracts dendritic cells (DC) into the porous device where the DCs are activated through contact with the adjuvant and the tumor antigens.  The Cellarium then enables the DCs to leave and migrate to the lymph nodes and the PLG scaffold dissolves like resorbable sutures.